Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Neuroendocrine differentiation (NED) secondary to androgen deprivation therapy (ADT) may be frequent in various stages of prostate cancer (PC), particularly in castration-resistant PC (CRPC). NED generally involves more aggressive PC clinical behavior and an unfavorable prognosis. The identification of neuropeptides secreted by NE cells and of different proliferative and anti-apoptotic pathways has led to attention being focused on probable diagnostic targets and therapeutic options for a subtype of PC. Emerging evidence suggests that the acquisition of epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) phenotype are associated with the development of NED in PC, responsible for a complex interaction between ADT, the onset of CRPC and NED, in which EMT and CSC could play a central role, providing potential therapeutic targets. In this article, we review the pathogenetic, prognostic and predictive significance of NED in human PC, providing an insight into innovative agents capable of treating and perhaps preventing NED occurrence.

Original languageEnglish
Pages (from-to)11-24
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Volume92
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Prostatic Neoplasms
Epithelial-Mesenchymal Transition
Neoplastic Stem Cells
Castration
Mesenchymal Stromal Cells
Androgens
Therapeutics
Neuropeptides
Phenotype

Keywords

  • Androgen deprivation therapy
  • Cancer stem cells
  • Chromogranin A
  • Epithelial-mesenchymal transition
  • Neuroendocrine differentiation
  • Prognosis
  • Prostate cancer
  • Somatostatin

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

@article{af0db73c39774ddaad045fa91fadbd19,
title = "Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies",
abstract = "Neuroendocrine differentiation (NED) secondary to androgen deprivation therapy (ADT) may be frequent in various stages of prostate cancer (PC), particularly in castration-resistant PC (CRPC). NED generally involves more aggressive PC clinical behavior and an unfavorable prognosis. The identification of neuropeptides secreted by NE cells and of different proliferative and anti-apoptotic pathways has led to attention being focused on probable diagnostic targets and therapeutic options for a subtype of PC. Emerging evidence suggests that the acquisition of epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) phenotype are associated with the development of NED in PC, responsible for a complex interaction between ADT, the onset of CRPC and NED, in which EMT and CSC could play a central role, providing potential therapeutic targets. In this article, we review the pathogenetic, prognostic and predictive significance of NED in human PC, providing an insight into innovative agents capable of treating and perhaps preventing NED occurrence.",
keywords = "Androgen deprivation therapy, Cancer stem cells, Chromogranin A, Epithelial-mesenchymal transition, Neuroendocrine differentiation, Prognosis, Prostate cancer, Somatostatin",
author = "Vincenza Conteduca and Michele Aieta and Dino Amadori and {De Giorgi}, Ugo",
year = "2014",
doi = "10.1016/j.critrevonc.2014.05.008",
language = "English",
volume = "92",
pages = "11--24",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Neuroendocrine differentiation in prostate cancer

T2 - Current and emerging therapy strategies

AU - Conteduca, Vincenza

AU - Aieta, Michele

AU - Amadori, Dino

AU - De Giorgi, Ugo

PY - 2014

Y1 - 2014

N2 - Neuroendocrine differentiation (NED) secondary to androgen deprivation therapy (ADT) may be frequent in various stages of prostate cancer (PC), particularly in castration-resistant PC (CRPC). NED generally involves more aggressive PC clinical behavior and an unfavorable prognosis. The identification of neuropeptides secreted by NE cells and of different proliferative and anti-apoptotic pathways has led to attention being focused on probable diagnostic targets and therapeutic options for a subtype of PC. Emerging evidence suggests that the acquisition of epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) phenotype are associated with the development of NED in PC, responsible for a complex interaction between ADT, the onset of CRPC and NED, in which EMT and CSC could play a central role, providing potential therapeutic targets. In this article, we review the pathogenetic, prognostic and predictive significance of NED in human PC, providing an insight into innovative agents capable of treating and perhaps preventing NED occurrence.

AB - Neuroendocrine differentiation (NED) secondary to androgen deprivation therapy (ADT) may be frequent in various stages of prostate cancer (PC), particularly in castration-resistant PC (CRPC). NED generally involves more aggressive PC clinical behavior and an unfavorable prognosis. The identification of neuropeptides secreted by NE cells and of different proliferative and anti-apoptotic pathways has led to attention being focused on probable diagnostic targets and therapeutic options for a subtype of PC. Emerging evidence suggests that the acquisition of epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) phenotype are associated with the development of NED in PC, responsible for a complex interaction between ADT, the onset of CRPC and NED, in which EMT and CSC could play a central role, providing potential therapeutic targets. In this article, we review the pathogenetic, prognostic and predictive significance of NED in human PC, providing an insight into innovative agents capable of treating and perhaps preventing NED occurrence.

KW - Androgen deprivation therapy

KW - Cancer stem cells

KW - Chromogranin A

KW - Epithelial-mesenchymal transition

KW - Neuroendocrine differentiation

KW - Prognosis

KW - Prostate cancer

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=84906937466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906937466&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2014.05.008

DO - 10.1016/j.critrevonc.2014.05.008

M3 - Article

C2 - 24952997

AN - SCOPUS:84906937466

VL - 92

SP - 11

EP - 24

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -